No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials
Executive Summary
Some of the biggest life science VCs are spending hundreds of millions of dollars to run the clinical trials of drugs owned by big drugmakers. But if the strategy works, they may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.
You may also be interested in...
CROs And Biopharma Weigh The Balance Of Risk And Responsibility
Biopharmaceutical companies have been outsourcing R&D activity to CROs for a while, but neither they nor CROs have sorted out which side should bear the burden of what kind of risk and how to best structure operations.
Xalkori And Inlyta: NICE Pans Two Pfizer Oncology Drugs In Two Days
Britain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma within two days of each other, putting drug discounts back in the spotlight.
Germany’s IQWiG Pans Pfizer’s Xalkori On Study Results, Side Effects
Germany’s IQWiG has shot down Pfizer’s lung cancer treatment, citing questionable study results and no improvement on curbing side effects.